Analytical Chemist
Contributor since: 2011
Latest Articles
Market Performance During Government Shutdown Predicts Future Market Performance
Apple: The Dangers Of Using Bad Data To Calculate Only One Metric
Why I Bought Linn Energy In My Roth IRA
An Attractive Arbitrage Opportunity In SuperValu
It Doesn't Matter Where Returns Come From: More Realistic Modeling Of Dividend Growth Investing
Booking First Class, Stuck In Steerage: Beware The Dangers Of Dual-Class Stocks
SuperValu Shorts Still Don't Get It
Pfizer's Declining R&D: Count Me Out
Misleading Payout Ratios In Emerging Market Telecoms
Visualizing Dividend Growth Rates
SuperValu Is Drastically Undervalued
DUSA Pharmaceuticals, Up 25% Tuesday, Still Has Room To Run
Misleading Dividend Payout Ratios In Small-Cap Telecom Stocks
Misleading Payout Ratios In International Telecommunications Stocks
Misleading Dividend Payout Ratios In Telecommunications Stocks
3 Paths For Dendreon As Provenge Plods Toward Profits
Street Overreacts To SuperValu Earnings; Provides Attractive Buy Opportunity
Pfizer Out Of Lipitor's Shadow, But Still Expects To Grow Profits
Transocean Ruling May Limit Oil Spill Liability
Amylin's Agreement with Lilly Will Not Lead It To Profitablity
Transocean Receives Favorable Ruling On Liability
Focus On Berkshire's Q3 Operating Earnings
An In-Depth Look At Berkshire Hathaway, Part 3: Burlington Northern Santa Fe
Will Abbott's Split Unlock Shareholder Value?
An In-Depth Look At Berkshire Hathaway, Part 2: Utilities And Energy
Oil Companies In Libya
Assessing EWZ: Brazilian Stocks Appear Undervalued
Dendreon and Provenge: Too High of a Risk for the Reward
An In-Depth Look at Berkshire Hathaway, Part 1: Insurance
Teva's Acquisition of Cephalon Is Another Buy Sign
Teva's Bad News Presents Buying Opportunity
Beyond Provenge: Dendreon Is Too Expensive for Value, Growth Investors